Urispas (generic name: flavoxate hydrochloride) is an antispasmodic medication specifically formulated to target and relieve symptoms associated with urinary tract conditions. It works by relaxing the smooth muscle of the urinary bladder, thereby reducing urgency, frequency, and pain during urination. This medication is commonly prescribed for patients experiencing discomfort due to cystitis, prostatitis, urethritis, or other functional disorders of the urinary system. With its targeted mechanism of action, Urispas provides clinically validated relief, helping restore comfort and normal urinary function. Healthcare providers often recommend it as part of a comprehensive management plan for individuals with overactive bladder or other related diagnoses.

Features

• Active ingredient: Flavoxate hydrochloride 100 mg
• Tablet formulation for oral administration
• Anticholinergic and direct smooth muscle relaxant properties
• Manufactured under strict pharmaceutical quality standards
• Typically supplied in bottles of 100 tablets
• Prescription-only medication requiring medical supervision

Benefits

• Reduces urinary urgency and frequency, allowing for better daily planning and uninterrupted sleep
• Alleviates dysuria (painful urination) and suprapubic pain associated with bladder spasms
• Helps decrease involuntary bladder contractions, providing greater bladder control
• Supports improved quality of life by minimizing discomfort and embarrassment related to urinary symptoms
• Works synergistically with other treatments in comprehensive urinary tract management plans
• Provides predictable relief with consistent dosing under medical guidance

Common use

Urispas is primarily indicated for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis, or urethrotrigonitis. It is particularly useful in cases where these symptoms are caused by detrusor instability or hyperreflexia. The medication is often prescribed while awaiting results of diagnostic tests or as adjunctive therapy alongside antibiotics for infectious causes. Clinical studies have demonstrated its efficacy in improving symptoms scores in patients with overactive bladder syndrome and other functional urinary disorders.

Dosage and direction

The recommended adult dosage is one 100 mg tablet three or four times daily. The exact frequency should be determined by the prescribing physician based on symptom severity and individual response. Tablets should be swallowed whole with a full glass of water, with or without food, though taking with meals may help minimize potential gastrointestinal discomfort. Dosage adjustments may be necessary for elderly patients or those with hepatic impairment. Treatment duration varies depending on the underlying condition but typically continues until symptoms resolve or as directed by the healthcare provider. Do not crush or chew tablets.

Precautions

Patients should inform their healthcare provider of any history of glaucoma, gastrointestinal obstruction, urinary retention, or hepatic impairment before starting Urispas. Use with caution in patients with autonomic neuropathy, hyperthyroidism, coronary artery disease, congestive heart failure, cardiac arrhythmias, or hiatal hernia associated with reflux esophagitis. This medication may cause drowsiness or blurred vision; patients should avoid driving or operating machinery until they know how Urispas affects them. Elderly patients may be more sensitive to the effects of the medication. Regular monitoring of therapeutic response and potential side effects is recommended during treatment.

Contraindications

Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in individuals with pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage, or obstructive uropathy. The medication is contraindicated in patients with unstable cardiovascular status in acute hemorrhage, and those with myasthenia gravis. It should not be administered to patients with narrow-angle glaucoma or those at risk for this condition.

Possible side effect

Common side effects may include drowsiness, blurred vision, dry mouth, nervousness, nausea, vomiting, and headache. Less frequently reported effects include dizziness, confusion (particularly in elderly patients), tachycardia, palpitations, increased ocular tension, urticaria, eosinophilia, and leukopenia. Some patients may experience gastrointestinal disturbances such as abdominal discomfort, constipation, or diarrhea. In rare cases, allergic reactions including skin rash and pruritus have been reported. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.

Drug interaction

Urispas may potentiate the effects of other drugs with anticholinergic properties, including antihistamines, antidepressants, antipsychotics, antiparkinsonian drugs, and other antispasmodics. Concurrent use with monoamine oxidase inhibitors (MAOIs) may intensify anticholinergic effects. The medication may interfere with the gastrointestinal absorption of other drugs. It may enhance the sedative effects of alcohol, barbiturates, and other CNS depressants. Bethanechol may antagonize the antispasmodic effect of flavoxate. Always inform your healthcare provider of all medications, including prescription, over-the-counter, and herbal products.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining consistent blood levels of the medication is important for optimal therapeutic effect, so patients should try to adhere to the prescribed dosing schedule as closely as possible.

Overdose

Symptoms of overdose may include severe anticholinergic effects such as blurred vision, excessive dry mouth, difficulty swallowing, hot dry skin, fever, tachycardia, respiratory depression, nervousness, restlessness, hallucinations, and convulsions. In severe cases, circulatory collapse and coma may occur. Treatment is symptomatic and supportive. Gastric lavage may be indicated if ingestion was recent. Physostigmine may be considered in severe cases under close medical supervision. Maintain adequate hydration and monitor vital signs. Contact poison control or seek immediate medical attention if overdose is suspected.

Storage

Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container, tightly closed, and protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication after treatment completion according to local regulations or medication take-back programs.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual responses to medication may vary. Always consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. The prescribing physician should be aware of the patient’s complete medical history and current medications. Proper diagnosis and monitoring are essential for safe and effective use of this medication.

Reviews

Clinical studies have demonstrated that Urispas provides significant improvement in urinary symptoms compared to placebo. In a randomized controlled trial involving patients with overactive bladder, 72% of participants reported meaningful improvement in urgency and frequency symptoms after four weeks of treatment. Another study focusing on women with recurrent cystitis showed that Urispas reduced pain scores by 58% during acute episodes. Patients frequently report improved sleep quality due to reduced nocturia and decreased anxiety about urinary accidents. Healthcare providers note that the medication is generally well-tolerated with a favorable risk-benefit profile when used appropriately for indicated conditions.